These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16094929)

  • 21. Overactive bladder: diagnosis and management.
    Robinson D; Cardozo L
    Maturitas; 2012 Feb; 71(2):188-93. PubMed ID: 22197347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of overactive bladder syndrome.
    Srikrishna S; Robinson D; Cardozo L; Vella M
    Postgrad Med J; 2007 Jul; 83(981):481-6. PubMed ID: 17621619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
    Homma Y; Paick JS; Lee JG; Kawabe K;
    BJU Int; 2003 Nov; 92(7):741-7. PubMed ID: 14616458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overactive bladder in children.
    Franco I
    Nat Rev Urol; 2016 Sep; 13(9):520-32. PubMed ID: 27530266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Augmentation enterocystoplasty in overactive bladder: is there still a role?
    Reyblat P; Ginsberg DA
    Curr Urol Rep; 2010 Nov; 11(6):432-9. PubMed ID: 20734172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacotherapy of overactive bladder.
    Athanasopoulos A
    Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In women with urinary incontinence how necessary is cystometry?
    Saleem A
    J Pak Med Assoc; 2010 May; 60(5):356-9. PubMed ID: 20527606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response.
    Malone-Lee J; Henshaw DJ; Cummings K
    BJU Int; 2003 Sep; 92(4):415-7. PubMed ID: 12930431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Overactive bladder--treatment with antimuscarinic agents].
    Höfner K
    Urologe A; 2003 Jun; 42(6):793-800. PubMed ID: 12851770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary incontinence in men: current and developing therapy options.
    Burden H; Abrams P
    Expert Opin Pharmacother; 2016; 17(5):715-26. PubMed ID: 26800277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intravesical treatment of overactive bladder syndrome].
    Haferkamp A; Hohenfellner M
    Urologe A; 2006 Oct; 45(10):1283-8. PubMed ID: 16972089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders.
    Liu HT; Chen CY; Kuo HC
    J Formos Med Assoc; 2010 Dec; 109(12):862-78. PubMed ID: 21195884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The medical treatment of overactive bladder].
    Beneton C; De Parisot O
    Neurochirurgie; 2003 May; 49(2-3 Pt 2):369-76. PubMed ID: 12746713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravesical therapy for overactive bladder.
    Evans RJ
    Curr Urol Rep; 2005 Nov; 6(6):429-33. PubMed ID: 16238916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
    Tubaro A; Puccini F; De Nunzio C
    Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on the pharmacologic management of overactive bladder: the present and the future.
    Ellsworth P; Kirshenbaum E
    Urol Nurs; 2010; 30(1):29-38, 53. PubMed ID: 20359143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of Overactive Bladder Symptoms After Radical Prostatectomy.
    Peyronnet B; Brucker BM
    Curr Urol Rep; 2018 Oct; 19(12):95. PubMed ID: 30306278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial.
    Burgio KL; Goode PS; Johnson TM; Hammontree L; Ouslander JG; Markland AD; Colli J; Vaughan CP; Redden DT
    J Am Geriatr Soc; 2011 Dec; 59(12):2209-16. PubMed ID: 22092152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.